Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

2.

Morgan

GJ

,

Walker

BA

,

Davies

FE

.

The genetic architecture of multiple myeloma

.

Nat Rev Cancer

.

2012

;

12

(

5

):

335

-

348

.

3.

Bolli

N

,

Avet-Loiseau

H

,

Wedge

DC

, et al.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

.

Nat Commun

.

2014

;

5

:

2997

.

4.

Ziccheddu

B

,

Biancon

G

,

Bagnoli

F

, et al.

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

.

Blood Adv

.

2020

;

4

(

5

):

830

-

844

.

5.

Manier

S

,

Salem

KZ

,

Park

J

,

Landau

DA

,

Getz

G

,

Ghobrial

IM

.

Genomic complexity of multiple myeloma and its clinical implications

.

Nat Rev Clin Oncol

.

2017

;

14

(

2

):

100

-

113

.

6.

Dutta

AK

,

Alberge

JB

,

Sklavenitis-Pistofidis

R

,

Lightbody

ED

,

Getz

G

,

Ghobrial

IM

.

Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine

.

Nat Rev Clin Oncol

.

2022

;

19

(

4

):

223

-

236

.

7.

Da Vià

MC

,

Dietrich

O

,

Truger

M

, et al.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

.

Nat Med

.

2021

;

27

(

4

):

616

-

619

.

8.

Tirier

SM

,

Mallm

JP

,

Steiger

S

, et al.

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics

.

Nat Commun

.

2021

;

12

(

1

):

6960

.

9.

Cohen

YC

,

Zada

M

,

Wang

SY

, et al.

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

.

Nat Med

.

2021

;

27

(

3

):

491

-

503

.

10.

Lareau

CA

,

Ludwig

LS

,

Muus

C

, et al.

Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling

.

Nat Biotechnol

.

2021

;

39

(

4

):

451

-

461

.

11.

Penter

L

,

Gohil

SH

,

Lareau

C

, et al.

Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history

.

Cancer Discov

.

2021

;

11

(

12

):

30483063

.

12.

Velten

L

,

Story

BA

,

Hernández-Malmierca

P

, et al.

Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics

.

Nat Commun

.

2021

;

12

(

1

):

1366

.

13.

Rasche

L

,

Schinke

C

,

Maura

F

, et al.

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states

.

Nat Commun

.

2022

;

13

(

1

):

4517

.

14.

Keats

JJ

,

Chesi

M

,

Egan

JB

, et al.

Clonal competition with alternating dominance in multiple myeloma

.

Blood

.

2012

;

120

(

5

):

1067

-

1076

.

15.

Weinhold

N

,

Ashby

C

,

Rasche

L

, et al.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

.

Blood

.

2016

;

128

(

13

):

1735

-

1744

.

16.

Maura

F

,

Bolli

N

,

Angelopoulos

N

, et al.

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

.

Nat Commun

.

2019

;

10

(

1

):

3835

.

17.

Corre

J

,

Cleynen

A

,

Robiou du Pont

S

, et al.

Multiple myeloma clonal evolution in homogeneously treated patients

.

Leukemia

.

2018

;

32

(

12

):

2636

-

2647

.

18.

Ledergor

G

,

Weiner

A

,

Zada

M

, et al.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

.

Nat Med

.

2018

;

24

(

12

):

1867

-

1876

.

19.

Frede

J

,

Anand

P

,

Sotudeh

N

, et al.

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma

.

Nat Cell Biol

.

2021

;

23

(

11

):

1199

-

1211

.

20.

Waldschmidt

JM

,

Kloeber

JA

,

Anand

P

, et al.

Single-cell profiling reveals metabolic reprogramming as a resistance mechanism in BRAF-mutated multiple myeloma

.

Clin Cancer Res

.

2021

;

27

(

23

):

6432

-

6444

.

21.

Sklavenitis-Pistofidis

R

,

Aranha

MP

,

Redd

RA

, et al.

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

.

Cancer Cell

.

2022

;

40

(

11

):

1358

-

1373.e8

.

22.

Reisinger

E

,

Genthner

L

,

Kerssemakers

J

, et al.

OTP: an automatized system for managing and processing NGS data

.

J Biotechnol

.

2017

;

261

:

53

-

62

.

23.

Giesen

N

,

Chatterjee

M

,

Scheid

C

, et al.

A phase II clinical trial of combined BRAF/MEK inhibition for BRAF V600E-mutated multiple myeloma

.

Blood

.

2023

;

141

(

14

):

1685

-

1690

.

24.

Rustad

EH

,

Nadeu

F

,

Angelopoulos

N

, et al.

mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies

.

Commun Biol

.

2021

;

4

(

1

):

424

.

25.

Stuart

T

,

Butler

A

,

Hoffman

P

, et al.

Comprehensive integration of single-cell data

.

Cell

.

2019

;

177

(

7

):

1888

-

1902.e21

.

26.

Jin

S

,

Guerrero-Juarez

CF

,

Zhang

L

, et al.

Inference and analysis of cell-cell communication using CellChat

.

Nat Commun

.

2021

;

12

(

1

):

1088

.

27.

Granja

JM

,

Corces

MR

,

Pierce

SE

, et al.

ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis

.

Nat Genet

.

2021

;

53

(

3

):

403

-

411

.

28.

van Dijk

D

,

Sharma

R

,

Nainys

J

, et al.

Recovering gene interactions from single-cell data using data diffusion

.

Cell

.

2018

;

174

(

3

):

716

-

729.e27

.

29.

Satpathy

AT

,

Granja

JM

,

Yost

KE

, et al.

Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion

.

Nat Biotechnol

.

2019

;

37

(

8

):

925

-

936

.

30.

Granja

JM

,

Klemm

S

,

McGinnis

LM

, et al.

Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia

.

Nat Biotechnol

.

2019

;

37

(

12

):

1458

-

1465

.

31.

Zhang

Y

,

Liu

T

,

Meyer

CA

, et al.

Model-based analysis of ChIP-Seq (MACS)

.

Genome Biol

.

2008

;

9

:

R137

.

32.

Khan

A

,

Fornes

O

,

Stigliani

A

, et al.

JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework

.

Nucleic Acids Res

.

2021

;

46

(

D1

):

D1284

. D266.

33.

Castro-Mondragon

JA

,

Riudavets-Puig

R

,

Rauluseviciute

I

, et al.

JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles

.

Nucleic Acids Res

.

2022

;

50

(

D1

):

D165

-

D173

.

34.

Mallm

J-P

,

Iskar

M

,

Ishaque

N

, et al.

Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks

.

Mol Syst Biol

.

2019

;

15

(

5

):

e8339

.

35.

Patel

AP

,

Tirosh

I

,

Trombetta

JJ

, et al.

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

.

Science

.

2014

;

344

(

6190

):

1396

-

1401

.

36.

Melchor

L

,

Brioli

A

,

Wardell

CP

, et al.

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

.

Leukemia

.

2014

;

28

(

8

):

1705

-

1715

.

37.

Ju

YS

,

Alexandrov

LB

,

Gerstung

M

, et al.

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

.

Elife

.

2014

;

3

:

e02935

.

38.

Yuan

Y

,

Ju

YS

,

Kim

Y

, et al.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

.

Nat Genet

.

2020

;

52

(

3

):

342

-

352

.

39.

Landau

HJ

,

Yellapantula

V

,

Diamond

BT

, et al.

Accelerated single cell seeding in relapsed multiple myeloma

.

Nat Commun

.

2020

;

11

(

1

):

3617

.

40.

Maura

F

,

Weinhold

N

,

Diamond

B

, et al.

The mutagenic impact of melphalan in multiple myeloma

.

Leukemia

.

2021

;

35

(

8

):

2145

-

2150

.

41.

Rustad

EH

,

Yellapantula

V

,

Leongamornlert

D

, et al.

Timing the initiation of multiple myeloma

.

Nat Commun

.

2020

;

11

(

1

):

1917

.

42.

Jannuzzi

AT

,

Arslan

S

,

Yilmaz

AM

, et al.

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

.

Redox Biol

.

2020

;

32

:

101502

.

43.

Sha

Z

,

Goldberg

AL

.

Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis

.

Proc Natl Acad Sci U S A

.

2020

;

117

(

35

):

21588

-

21597

.

44.

Shah

SP

,

Nooka

AK

,

Jaye

DL

,

Bahlis

NJ

,

Lonial

S

,

Boise

LH

.

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation

.

Oncotarget

.

2016

;

7

(

37

):

59727

-

59741

.

45.

Arozarena

I

,

Wellbrock

C

.

Overcoming resistance to BRAF inhibitors

.

Ann Transl Med

.

2017

;

5

(

19

):

387

.

46.

Zhang

Q

,

Liu

W

,

Zhang

HM

, et al.

hTFtarget: a comprehensive database for regulations of human transcription factors and their targets

.

Genomics Proteomics Bioinformatics

.

2020

;

18

(

2

):

120

-

128

.

47.

University, B

.

NFKB target genes

. Accessed 11 October 2022. https://www.bu.edu/nf-kb/gene-resources/target-genes/.

48.

Luger

D

,

Yang

YA

,

Raviv

A

, et al.

Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects

.

PLoS One

.

2013

;

8

(

10

):

e76115

.

49.

Monroe

JG

.

ITAM-mediated tonic signalling through pre-BCR and BCR complexes

.

Nat Rev Immunol

.

2006

;

6

(

4

):

283

-

294

.

50.

Kawakubo

H

,

Carey

JL

,

Brachtel

E

, et al.

Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer

.

Oncogene

.

2004

;

23

(

50

):

8310

-

8319

.

51.

Demchenko

YN

,

Kuehl

WM

.

A critical role for the NFkB pathway in multiple myeloma

.

Oncotarget

.

2010

;

1

:

59

-

68

.

52.

Munawar

U

,

Roth

M

,

Barrio

S

, et al.

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model

.

Sci Rep

.

2019

;

9

(

1

):

18062

.

53.

Munawar

U

,

Rasche

L

,

Müller

N

, et al.

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness

.

Blood

.

2019

;

134

(

10

):

836

-

840

.

54.

Suzuki

R

,

Ogiya

D

,

Ogawa

Y

,

Kawada

H

,

Ando

K

.

Targeting CAM-DR and mitochondrial transfer for the treatment of multiple myeloma

.

Curr Oncol

.

2022

;

29

(

11

):

8529

-

8539

.

55.

Bjorklund

CC

,

Baladandayuthapani

V

,

Lin

HY

, et al.

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

.

Leukemia

.

2014

;

28

(

2

):

373

-

383

.

56.

Neri

P

,

Bahlis

NJ

.

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma

.

Curr Cancer Drug Targets

.

2012

;

12

(

7

):

776

-

796

.

57.

Giesen

N

,

Paramasivam

N

,

Toprak

UH

, et al.

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

.

Haematologica

.

2022

;

107

(

8

):

1891

-

1901

.

58.

Hansson

M

,

Gimsing

P

,

Badros

A

, et al.

A phase I dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma

.

Clin Cancer Res

.

2015

;

21

(

12

):

2730

-

2736

.

59.

Chen

X

,

Wong

OK

,

Post

L

.

CD38 x ICAM1 bispecific antibody is a novel approach for treating multiple myeloma and lymphoma [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

2413

.

60.

Sherbenou

DW

,

Su

Y

,

Behrens

CR

, et al.

Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma

.

Clin Cancer Res

.

2020

;

26

(

22

):

6028

-

6038

.

61.

ICAM1-targeted immunotherapy is effective in multiple myeloma

.

Cancer Discov

.

2013

;

3

:

602

.

62.

Veitonmäki

N

,

Hansson

M

,

Zhan

F

, et al.

A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo

.

Cancer Cell

.

2013

;

23

(

4

):

502

-

515

.

63.

Agnarelli

A

,

Chevassut

T

,

Mancini

EJ

.

IRF4 in multiple myeloma-Biology, disease and therapeutic target

.

Leuk Res

.

2018

;

72

:

52

-

58

.

64.

Shaffer

AL

,

Emre

NCT

,

Lamy

L

, et al.

IRF4 addiction in multiple myeloma

.

Nature

.

2008

;

454

(

7201

):

226

-

231

.

65.

Zhu

YX

,

Shi

CX

,

Bruins

LA

, et al.

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

.

Blood Cancer J

.

2019

;

9

(

2

):

19

.

66.

Mondala

PK

,

Vora

AA

,

Zhou

T

, et al.

Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption

.

Cell Stem Cell

.

2021

;

28

(

4

):

623

-

636.e9

.

67.

Ueno

N

,

Nishimura

N

,

Ueno

S

, et al.

1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4

.

Oncogene

.

2017

;

36

(

31

):

4481

-

4497

.

68.

Ohguchi

H

,

Hideshima

T

,

Bhasin

MK

, et al.

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival

.

Nat Commun

.

2016

;

7

:

10258

.

69.

Fedele

PL

,

Liao

Y

,

Gong

JN

, et al.

The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival

.

Leukemia

.

2021

;

35

(

7

):

2114

-

2118

.

70.

Morelli

E

,

Leone

E

,

Cantafio

MEG

, et al.

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

.

Leukemia

.

2015

;

29

(

11

):

2173

-

2183

.

71.

Li

N

,

Johnson

DC

,

Weinhold

N

, et al.

Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression

.

Nat Commun

.

2016

;

7

:

13656

.

72.

Jin

Y

,

Chen

K

,

De Paepe

A

, et al.

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma

.

Blood

.

2018

;

131

(

19

):

2138

-

2150

.

73.

Ordoñez

R

,

Kulis

M

,

Russiñol

N

, et al.

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

.

Genome Res

.

2020

;

30

(

9

):

1217

-

1227

.

74.

Annunziata

CM

,

Davis

RE

,

Demchenko

Y

, et al.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

.

Cancer Cell

.

2007

;

12

(

2

):

115

-

130

.

75.

Hideshima

T

,

Chauhan

D

,

Richardson

P

, et al.

NF-kappa B as a therapeutic target in multiple myeloma

.

J Biol Chem

.

2002

;

277

(

19

):

16639

-

16647

.

76.

Nelson

EA

,

Walker

SR

,

Kepich

A

, et al.

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

.

Blood

.

2008

;

112

(

13

):

5095

-

5102

.

77.

Ogiya

D

,

Liu

J

,

Ohguchi

H

, et al.

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

.

Blood

.

2020

;

136

(

20

):

2334

-

2345

.

78.

Huang

Y-H

,

Molavi

O

,

Alshareef

A

, et al.

Constitutive activation of STAT3 in myeloma cells cultured in a three-dimensional, reconstructed bone marrow model

.

Cancers (Basel)

.

2018

;

10

(

6

):

206

.

79.

Yaccoby

S

,

Epstein

J

,

Qu

P

, et al.

Melphalan affects genes critical for myeloma survival, homing, and response to cytokines and chemokines

.

Blood

.

2015

;

126

(

23

):

1808

.

80.

Goicoechea

I

,

Puig

N

,

Cedena

MT

, et al.

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

.

Blood

.

2021

;

137

(

1

):

49

-

60

.

81.

Manier

S

,

Kawano

Y

,

Bianchi

G

,

Roccaro

AM

,

Ghobrial

IM

.

Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma

.

Curr Opin Hematol

.

2016

;

23

(

4

):

426

-

433

.

82.

Zhao

T

,

Chiang

ZD

,

Morriss

JW

, et al.

Spatial genomics enables multi-modal study of clonal heterogeneity in tissues

.

Nature

.

2022

;

601

(

7891

):

85

-

91

.

83.

Black

S

,

Phillips

D

,

Hickey

JW

, et al.

CODEX multiplexed tissue imaging with DNA-conjugated antibodies

.

Nat Protoc

.

2021

;

16

(

8

):

3802

-

3835

.

84.

Samur

MK

,

Fulciniti

M

,

Aktas Samur

A

, et al.

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

.

Nat Commun

.

2021

;

12

(

1

):

868

.

85.

Nijhof

IS

,

Casneuf

T

,

van Velzen

J

, et al.

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

.

Blood

.

2016

;

128

(

7

):

959

-

970

.

86.

Frick

C

,

Odermatt

A

,

Zen

K

, et al.

Interaction of ICAM-1 with beta 2-integrin CD11c/CD18: characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1

.

Eur J Immunol

.

2005

;

35

(

12

):

3610

-

3621

.

87.

Moser-Katz

T

,

Joseph

NS

,

Dhodapkar

MV

,

Lee

KP

,

Boise

LH

.

Game of bones: how myeloma manipulates its microenvironment

.

Front Oncol

.

2020

;

10

:

625199

.